ArticleLeukemia research reports2021

Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax.

Maria Tariq Siddiqui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.